A critical review of definitions used to describe Pseudomonas aeruginosa microbiological status in patients with cystic fibrosis for application in clinical trials-Reference-Cited by-同舟云学术

A critical review of definitions used to describe Pseudomonas aeruginosa microbiological status in patients with cystic fibrosis for application in clinical trials

Published:2020-01 Issue:1 Volume:19 Page:52-67
ISSN:1569-1993
Container-title:Journal of Cystic Fibrosis
language:en
Short-container-title:Journal of Cystic Fibrosis

Author:

Taccetti G.^ORCID,Denton M.,Hayes K.,Drevinek P.^ORCID,Sermet-Gaudelus I.,Bilton Diana,Campana Silvia,Dolce Daniela,Ferroni Agnes,Héry-Arnaud Geneviève,Martin-Gomez Marie-Teresa,Nash Edward,Pereira Luísa,Pressler Tanja,Tümmler Burkhard

Funder

PTC Therapeutics

CTN Standardization Microbiology Group

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Reference113 articles.

1. Disease-specific clinical trials networks: the example of cystic fibrosis;De Boeck;Eur J Pediatr,2016

2. In vitro antibiotic susceptibility of initial Pseudomonas aeruginosa isolates from United States cystic fibrosis patients;Van Devanter;J Ped Infect Dis Soc,2015

3. Prevention of Pseudomonas aeruginosa infection on patients with cystic fibrosis;Döring;Int J Med Microbiol,2010

4. Report of the workshop on endpoints for cystic fibrosis clinical trials;European Medicines Agency (EMA) Report,2012

5. Economic burden of Pseudomonas aeruginosa infection on patients with cystic fibrosis;Sansgiry;J Med Econ,2012

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis;Clinical Microbiology Reviews;2024-09-12

2. Monitoring cystic fibrosis airway infections with Pseudomonas aeruginosa with anti-OprF serum antibodies;Journal of Cystic Fibrosis;2024-06

3. Considerations for the use of inhaled antibiotics forPseudomonas aeruginosain people with cystic fibrosis receiving CFTR modulator therapy;BMJ Open Respiratory Research;2024-05

4. Pf4 Phage Variant Infection Reduces Virulence-Associated Traits in Pseudomonas aeruginosa;Microbiology Spectrum;2022-10-26

5. Alkyl-Quinolones derivatives as potential biomarkers for Pseudomonas aeruginosa infection chronicity in Cystic Fibrosis;Scientific Reports;2021-10-20